Filing Details
- Accession Number:
- 0001725160-22-000036
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-14 21:11:08
- Reporting Period:
- 2022-02-10
- Accepted Time:
- 2022-02-14 21:11:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1725160 | Zentalis Pharmaceuticals Inc. | ZNTL | Pharmaceutical Preparations (2834) | 823607803 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1807484 | D. Kevin Bunker | C/O Zentalis Pharmaceuticals, Inc. 1359 Broadway Suite 1710 New York NY 10018 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-02-10 | 22,481 | $0.00 | 768,798 | No | 4 | A | Direct | |
Common Stock | Disposition | 2022-02-10 | 2,366 | $52.15 | 177,634 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2022-02-10 | 3,074 | $53.19 | 174,560 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2022-02-10 | 3,321 | $54.20 | 171,239 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2022-02-10 | 1,239 | $54.96 | 170,000 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2022-02-14 | 1,622 | $50.16 | 767,176 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-02-14 | 203 | $50.75 | 766,973 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-02-14 | 2,863 | $50.29 | 764,110 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-02-10 | 52,745 | $0.00 | 52,745 | $52.61 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
52,745 | 2032-02-09 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 350 | Indirect | As UTMA custodian for sons |
Footnotes
- Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.68 to $52.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.69 to $53.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.71 to $54.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.72 to $55.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.97 to $50.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.